| Indicators | Browse All

Keros Therapeutics, Inc. (KROS)

Healthcare | Biotechnology | Lexington, United States | NasdaqGM
11.10 USD -0.70 (-5.932%) ⇩ (July 13, 2026, 4 p.m. EDT)

Short-term:★★☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 5:24 a.m. EDT

The investment case here is fundamentally broken. The company is hemorrhaging cash with negative free cash flow and operating margins of -70%, while revenue has collapsed by nearly 99% year-over-year. The balance sheet, though currently showing a high current ratio, is propped up by minimal debt relative to massive cash reserves that are being burned rapidly; this is a classic 'cash burn' trap where the runway is finite without a proven product launch. The price action confirms this deterioration, having lost over 55% of its value over the last five years, including a catastrophic 68% drop in the most recent fiscal year. While the short-term chart shows a slight bounce off the lows, the underlying business metrics—negative earnings, shrinking sales, and no dividend support—make this a severe avoid. The options market agrees, with traders stacking protection rather than betting on a rally.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.059541
AutoETS0.075396
AutoARIMA0.078344
MSTL0.079490

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 49%
H-stat 0.65
Ljung-Box p 0.000
Jarque-Bera p 0.416
Excess Kurtosis -0.96
Attribute Value
Sector Healthcare
Debt to Equity Ratio 5.711
Revenue per Share 1.037
Market Cap 219,689,392
Forward P/E -1.98
Beta 0.97
Profit Margins -256.60%
Website https://www.kerostx.com

As of July 11, 2026, 5:24 a.m. EDT: Speculators are positioning defensively with heavy put volume and open interest concentrated at strikes below the current price ($10.00 and $12.50), while call activity remains sparse and focused on out-of-the-money strikes. This imbalance suggests a market expectation of further downside or a lack of conviction in a near-term recovery, despite some minor call flow at lower strikes.


Info Dump

Attribute Value
52 Week Change -0.1901167
Address1 1,050 Waltham Street
Address2 Suite 302
All Time High 88.8
All Time Low 9.12
Ask 14.19
Ask Size 2
Audit Risk 6
Average Daily Volume10 Day 410,130
Average Daily Volume3 Month 313,368
Average Volume 313,368
Average Volume10Days 410,130
Beta 0.97
Bid 8.31
Bid Size 2
Board Risk 5
Book Value 14.475
City Lexington
Compensation As Of Epoch Date 1,767,139,200
Compensation Risk 7
Country United States
Crypto Tradeable 0
Currency USD
Current Price 11.1
Current Ratio 22.615
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 11.78
Day Low 11.0
Debt To Equity 5.711
Display Name Keros Therapeutics
Earnings Timestamp 1,778,761,800
Earnings Timestamp End 1,785,933,000
Earnings Timestamp Start 1,785,933,000
Ebitda -105,780,000
Ebitda Margins 0.0
Enterprise To Ebitda 0.43
Enterprise To Revenue -1.371
Enterprise Value -45,496,608
Eps Current Year -5.186
Eps Forward -5.59333
Eps Trailing Twelve Months -2.53
Esg Populated 0
Exchange NGM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 10.9852
Fifty Day Average Change 0.11480045
Fifty Day Average Change Percent 0.010450466
Fifty Two Week Change Percent -19.011671
Fifty Two Week High 22.55
Fifty Two Week High Change -11.449999
Fifty Two Week High Change Percent -0.5077605
Fifty Two Week Low 9.69
Fifty Two Week Low Change 1.4100008
Fifty Two Week Low Change Percent 0.14551093
Fifty Two Week Range 9.69 - 22.55
Financial Currency USD
First Trade Date Milliseconds 1,586,352,600,000
Float Shares 17,798,403
Forward Eps -5.59333
Forward P E -1.9845066
Free Cashflow -37,688,500
Full Exchange Name NasdaqGM
Full Time Employees 87
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,782,864,000
Gross Margins -1.84886
Gross Profits -61,349,000
Has Pre Post Market Data 1
Held Percent Insiders 0.03709
Held Percent Institutions 0.95706004
Implied Shares Outstanding 19,791,837
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Long Name Keros Therapeutics, Inc.
Market us_market
Market Cap 219,689,392
Market State PRE
Max Age 86,400
Message Board Id finmb_333195513
Most Recent Quarter 1,774,915,200
Net Income To Common -85,145,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 219,689,390
Number Of Analyst Opinions 6
Open 11.78
Operating Cashflow -57,195,000
Operating Margins -70.509544
Overall Risk 7
Payout Ratio 0.0
Phone 617 314 6297
Previous Close 11.8
Price Eps Current Year -2.140378
Price Hint 2
Price To Book 0.7668394
Price To Sales Trailing12 Months 6.62074
Profit Margins -2.566
Quick Ratio 22.174
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.7
Regular Market Change Percent -5.9322
Regular Market Day High 11.78
Regular Market Day Low 11.0
Regular Market Day Range 11.0 - 11.78
Regular Market Open 11.78
Regular Market Previous Close 11.8
Regular Market Price 11.1
Regular Market Time 1,783,972,801
Regular Market Volume 250,130
Return On Assets -0.12234
Return On Equity -0.16785999
Revenue Growth -0.998
Revenue Per Share 1.037
Sand P52 Week Change 0.20847368
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 7
Shares Outstanding 19,791,837
Shares Percent Shares Out 0.0519
Shares Short 1,026,323
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 1,508,786
Short Name Keros Therapeutics, Inc.
Short Percent Of Float 0.059699997
Short Ratio 3.35
Source Interval 15
State MA
Symbol KROS
Target High Price 30.0
Target Low Price 16.0
Target Mean Price 21.83333
Target Median Price 20.0
Total Cash 281,496,992
Total Cash Per Share 14.223
Total Debt 16,311,000
Total Revenue 33,182,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -2.53
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 14.654125
Two Hundred Day Average Change -3.5541248
Two Hundred Day Average Change Percent -0.24253409
Type Disp Equity
Volume 250,130
Website https://www.kerostx.com
Zip 2,421